Personalised disease prevention

Average Ratings Feasibility

Diseases develop as a consequence of inherited susceptibilities and environmental exposure. Earlier intervention could clearly reduce the costs and the disease burden with major societal impacts in health and life-style. With modern science and technology including rapid evolving fields such as genomics, proteomics, and metabolomics, the ability to predict events and interfere before damage occurs is possible. Individuals will be evaluated to determine their baseline risk for various diseases, their current health status, and the likelihood of their developing specific clinical problems given their risks. In order for this to be possible one must acquire the tools like predictive biomarkers. These biomarkers would be identified and tracked over time to determine whether the individual’s likelihood of developing any particular disease is increasing or decreasing. For individuals that are identified to be high risk they will undergo extensive surveillance to track the disease as much as possible and to provide therapeutic support, such as with breast cancer. With any disease for personalized prevention and early intervention, it is necessary to predict baseline risks, provide surveillance for early detection, and facilitate optimal individualized therapy if disease develops. The first solutions are likely to emerge in specific areas where conventional treatments are not sufficient and there are first clinical applications. It is possible that this happens both through public sector financed initiatives and in the private markets.

Future Developments

The institutionalisation of the approach in healthcare would require the development of math models and data collection as a guideline to help standardize care. The models can then be used to identify risk prediction factors for particular diseases and a specific person’s profile.

The development of models and the collection of data require wide healthcare sector collaboration. Breakthroughs in such more personalised prevention have potentially far reaching economic and social impacts that would justify investments in coordinated European R&D efforts and market deployment. Increased predictive power is likely to attract the health insurance companies and subsequently also raise several data privacy issues that need to be addressed in a coordinated manner, in which European institutions and programmes could be in a relevant role.

Ref: Prospective health care: the second transformation of medicine


Image: Libertas Academica via photopin cc

4 Responses to “Personalised disease prevention”

  1. With regard to integrate molecular and genetic data it has been argued, especially by researchers working across the boundaries of medicine and informatics, that the current limitations of PHS is that they are capable of capturing only intermediate phenotypes (biochemical and physiological values) at best, while they have little or no capability to incorporate the assessment of environmental factors and of genetic information. As in the timeframe of 2020 it will probably be possible to have the personal genome in a few hours and at low cost, genetic and environmental factors should be included into PHS to increase their capacity of producing personalised and individualised early diagnosis, treatment and prevention.

    Ref. Personal Health Systems: a roadmap to 2020


Leave a Comment

You must be logged in to post a comment. Log in »

© 2012 PHS Foresight / contact: / Privacy Policy
Powered by Impetu Solutions
  • Recent Comments

  • Keywords

  • Ideas by Category

  • Flipboard

  • Contact us


    Your email was successfully sent. Your enquiry will be dealt with as soon as possible.

    error key Required fields not completed correctly.

  • Follow us